Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors

Equality Impact Assessment (Guidance development) (PDF 143 KB)

Final draft guidance

Final appraisal document (PDF 213 KB)

Public committee slides (PDF 665 KB)

Committee papers (PDF 11.06 MB)

Final scope (PDF 224 KB)

Final stakeholder list (PDF 164 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 220 KB)

Equality impact assessment (Scoping) (PDF 122 KB)

Draft scope post referral (PDF 217 KB)

Draft matrix post referral (PDF 164 KB)